Strategic Partnerships Leverage Minapharm’s dual presence in Egypt and Europe (Berlin subsidiary ProBioGen) to propose regional collaboration deals, technology licensing, or co-development programs that capitalize on their gene-to-market capabilities and immunotherapy pipeline.

CEPI Funding Momentum Capitalize on recent CEPI funding for an Ebola vaccine to position complementary vaccine development, clinical trial support, or supply chain and manufacturing services that align with their expanded vaccine portfolio and Africa-focused trials.

Expansion Financing Target growth capital needs stemming from their €15–€17 million loan and recent $16.5 million CEPI investment to offer strategic financing, contract manufacturing, or equipment upgrades that accelerate expansion into new facilities and bioprocess capabilities.

Immunotherapy Focus Align sales efforts with their immunotherapy R&D by offering specialized bioprocessing, cell culture, and GMP manufacturing services, as well as partnerships for clinical-grade biologics production and scale-up.

Regional Market Growth Position complementary products and services for growth in Egypt and MENA by addressing regulatory support, supply chain resilience, and local manufacturing capabilities to meet their broad product portfolio of life-saving therapies.